PARP1 and cancer: Recently, significant work in the area of synthetic lethality has led to new approaches for the treatment of BRCA1/2-deficient cancers using high efficacy poly(ADP-ribose) polymerase 1 (PARP1) inhibitors (PARPi) with high efficiency [20-24].